Bio-Rad Laboratories
BIO
367.92
-0.91
-0.25%
Bio-Rad Laboratories
US · BIO
#1479 by market cap
Listed 1970
367.92
-0.91
-0.25%
Live - 5344 symbols - heartbeat 435s ago
· 2026-10-07 19:54
After-hours
367.12
-0.22%
- Market cap
- 9.84B
- P/E (TTM)i
- 44.81
- P/Bi
- 1.37
- EPSi
- 27.85
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on BIO?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
Clear Street Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $38Market Newswire · 2026/9/29
-
Rating change
Wedbush Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $28Market Newswire · 2026/9/29
-
H.C. Wainwright Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/10/5
-
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $390Market Newswire · 2026/9/28
-
Rating change
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/9/29
-
Rating change
H.C. Wainwright Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/10/1
-
Rating change
Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2Market Newswire · 2026/9/30
-
Rating change
Stifel Maintains Braveheart Bio(BRVE.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/10/1
-
Company notice
Huaheng Bio: Implementation and Assessment Management Measures for the 2026 Restricted Stock Incentive Plan of Anhui Huaheng Biotechnology Co., Ltd.SZSI · 2026/9/30
-
Citi Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/10/2
-
Rating change
Clear Street Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $38Market Newswire · 2026/10/1
-
Rating change
Citi Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $12Market Newswire · 2026/9/30
-
Company notice
Climb Bio | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.SEC · 2026/10/1
-
Company notice
Shengda Bio: Announcement on the Establishment of a Dedicated Settlement Account for Cash Management of Raised Funds and Progress in Utilizing Idle Raised Funds for Cash Management by Zhejiang Shengda Bio‑Pharmaceutical Co., Ltd.SZSI · 2026/10/1
-
Company notice
Chengda Bio: Materials for the Second Extraordinary Shareholders' Meeting of Liaoning Chengda Bio Co., Ltd. for 2026SZSI · 2026/10/1
-
Company notice
L&C BIO Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major ShareholdersOPENDART · 2026/9/30
-
Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $59Market Newswire · 2026/10/1
-
Jefferies Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/10/1
-
Rating change
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/9/30
-
Rating change
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32Market Newswire · 2026/10/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.